PL2571503T3 - Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń - Google Patents
Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeńInfo
- Publication number
- PL2571503T3 PL2571503T3 PL11781422T PL11781422T PL2571503T3 PL 2571503 T3 PL2571503 T3 PL 2571503T3 PL 11781422 T PL11781422 T PL 11781422T PL 11781422 T PL11781422 T PL 11781422T PL 2571503 T3 PL2571503 T3 PL 2571503T3
- Authority
- PL
- Poland
- Prior art keywords
- disorders
- compositions
- inflammatory disease
- treating neoplasia
- neoplasia
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33499110P | 2010-05-14 | 2010-05-14 | |
| US37074510P | 2010-08-04 | 2010-08-04 | |
| US37586310P | 2010-08-22 | 2010-08-22 | |
| US201161467376P | 2011-03-24 | 2011-03-24 | |
| PCT/US2011/036701 WO2011143669A2 (en) | 2010-05-14 | 2011-05-16 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| EP11781422.8A EP2571503B1 (en) | 2010-05-14 | 2011-05-16 | Compositions and their use in treating neoplasia, inflammatory disease and other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2571503T3 true PL2571503T3 (pl) | 2015-06-30 |
Family
ID=44915031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11781422T PL2571503T3 (pl) | 2010-05-14 | 2011-05-16 | Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń |
| PL14197043T PL2902030T3 (pl) | 2010-05-14 | 2011-05-16 | Związki tienotriazolodiazepinowe do leczenia nowotworu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14197043T PL2902030T3 (pl) | 2010-05-14 | 2011-05-16 | Związki tienotriazolodiazepinowe do leczenia nowotworu |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8981083B2 (pl) |
| EP (2) | EP2571503B1 (pl) |
| KR (1) | KR101857599B1 (pl) |
| CN (2) | CN103037865B (pl) |
| AU (1) | AU2011252808B2 (pl) |
| BR (2) | BR122014024883A2 (pl) |
| CA (1) | CA2799420C (pl) |
| DK (1) | DK2571503T3 (pl) |
| ES (2) | ES2606958T3 (pl) |
| HU (1) | HUE031073T2 (pl) |
| IL (3) | IL222993A (pl) |
| MX (3) | MX384074B (pl) |
| PL (2) | PL2571503T3 (pl) |
| PT (1) | PT2571503E (pl) |
| SI (1) | SI2902030T1 (pl) |
| WO (1) | WO2011143669A2 (pl) |
Families Citing this family (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033268A2 (en) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| KR102149860B1 (ko) * | 2012-02-27 | 2020-08-31 | 브리티쉬 콜롬비아 캔써 에이전시 브랜치 | 암의 후생적 결함을 교정하기 위한 작동자 단백질의 상호작용을 리프로그래밍하는 방법 |
| WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| US20150167062A1 (en) | 2012-06-14 | 2015-06-18 | Whitehead Institute For Biomedical Research | Genome-wide Method of Assessing Interactions Between Chemical Entities And Their Target Molecules |
| EP2861255B1 (en) | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| CA2877434A1 (en) * | 2012-06-25 | 2014-01-03 | Oncoethix Sa | Method of treating lymphoma using thienotriazolodiazepine compounds |
| US9610332B2 (en) | 2012-07-18 | 2017-04-04 | Massachusetts Institute Of Technology | Compositions and methods for modulating BRD4 bioactivity |
| JP6333251B2 (ja) | 2012-08-16 | 2018-05-30 | バイエル ファーマ アクチエンゲゼルシャフト | ２，３−ベンゾジアゼピン類 |
| WO2014048945A1 (de) | 2012-09-28 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CA2896053A1 (en) | 2012-12-21 | 2014-06-26 | Ocata Therapeutics, Inc. | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| CA2901352A1 (en) | 2013-02-19 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines |
| CA2901805A1 (en) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| HK1212972A1 (zh) | 2013-02-22 | 2016-06-24 | Bayer Pharma Aktiengesellschaft | 作爲bet-蛋白抑制剂用於治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓 |
| JP2016510039A (ja) * | 2013-02-28 | 2016-04-04 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法 |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| WO2014159392A1 (en) * | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| EA035469B1 (ru) | 2013-03-15 | 2020-06-22 | Инсайт Холдингс Корпорейшн | Трициклические гетероциклы как ингибиторы белков бэт |
| EA027139B1 (ru) | 2013-04-26 | 2017-06-30 | Бейджин, Лтд. | Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны |
| CA2913741A1 (en) * | 2013-05-28 | 2014-12-04 | The Brigham And Women's Hospital, Inc. | Bet inhibition therapy for heart disease |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| CN105473581B (zh) | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| HK1223364A1 (zh) * | 2013-06-28 | 2017-07-28 | Abbvie Inc. | 布罗莫结构域抑制剂 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| WO2015018523A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| US9676790B2 (en) | 2013-08-30 | 2017-06-13 | Concert Pharmaceuticals, Inc. | Substituted thienotriazolodiazapines |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US11446309B2 (en) * | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015078931A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating neuroblastomas using thienotriazolodiazepine compounds |
| JP2016538310A (ja) | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| CN105813643A (zh) * | 2013-11-27 | 2016-07-27 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑二氮杂*化合物的药物制剂治疗非小细胞肺癌的方法 |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| WO2015112809A2 (en) * | 2014-01-24 | 2015-07-30 | The Brigham And Women's Hospital, Inc. | Nsd3 inhibitors for treatment of cancers |
| WO2015117083A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| WO2015120393A1 (en) * | 2014-02-10 | 2015-08-13 | Concert Pharmaceuticals, Inc. | Substituted triazolobenzodiazepines |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| WO2015131113A1 (en) * | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| WO2015144636A1 (en) | 2014-03-24 | 2015-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of t-cell acute lymphoblastic leukemias |
| WO2015156601A1 (en) | 2014-04-09 | 2015-10-15 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| EP4649963A3 (en) * | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| SMT202000133T1 (it) | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015168621A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
| JP2017514907A (ja) * | 2014-05-02 | 2017-06-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法 |
| JP2017519727A (ja) | 2014-05-08 | 2017-07-20 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 |
| CA2951211A1 (en) * | 2014-06-13 | 2015-12-17 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
| CN106687463B (zh) | 2014-06-20 | 2019-04-09 | 星座制药公司 | 一种乙酰胺类化合物的晶型 |
| RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| WO2016022970A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| CN107427524A (zh) * | 2014-08-28 | 2017-12-01 | 翁科埃斯克斯有限公司 | 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法 |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| UA122130C2 (uk) * | 2014-10-27 | 2020-09-25 | Тенша Терапеутікс, Інк. | Інгібітори бромодомену |
| CA2964629A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| US20170335284A1 (en) * | 2014-11-07 | 2017-11-23 | Osaka University | Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| HK1245246A1 (zh) | 2014-12-01 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 作为溴域抑制剂的取代吡啶酮 |
| RU2745999C1 (ru) * | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN104610255B (zh) * | 2015-01-28 | 2017-01-18 | 常州工程职业技术学院 | 含有异噁唑骨架的[1,2‑a]咪唑并吡啶类衍生物的合成方法 |
| EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| US20180346988A1 (en) * | 2015-05-04 | 2018-12-06 | The Brigham And Women's Hospital, Inc. | Znf532 for diagnosis and treatment of cancer |
| WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
| CA2988414C (en) * | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| AU2016283020A1 (en) | 2015-06-26 | 2018-01-04 | Tensha Therapeutics, Inc. | Treatment of nut midline carcinoma |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) * | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | inhibitor resistance mechanism |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017037567A1 (en) * | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| MA43037A (fr) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Inst Inc | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| CA3014644A1 (en) | 2016-02-15 | 2017-08-24 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors |
| US10517877B2 (en) | 2016-03-30 | 2019-12-31 | Wisconsin Alumni Research Foundation | Compounds and methods for modulating frataxin expression |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| EP3440082A1 (en) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| AU2017251537B2 (en) | 2016-04-15 | 2020-10-08 | Abbvie Inc. | Bromodomain inhibitors |
| WO2017184999A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
| DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
| CN109715625B (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| EP3478824A1 (en) | 2016-07-01 | 2019-05-08 | Centre National de la Recherche Scientifique - CNRS | Amplifying beta cell differentiation with small molecules bet (bromodomain and extraterminal family of bromodomain-containing proteins) inhibitors |
| CA3036834A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| ES2857743T3 (es) | 2016-09-13 | 2021-09-29 | Univ Michigan Regents | 1,4-diazepinas fusionadas como degradadores de proteína BET |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| MX2019006956A (es) * | 2016-12-16 | 2019-08-01 | Hoffmann La Roche | Proceso para la fabricacion de derivados de diazepina. |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP3577120A1 (en) | 2017-02-03 | 2019-12-11 | The Regents of The University of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| US11759533B2 (en) | 2017-03-29 | 2023-09-19 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating gene expression |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019014514A1 (en) | 2017-07-14 | 2019-01-17 | University Of Massachusetts | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| JP2020528061A (ja) | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法 |
| WO2019020610A1 (en) | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| US11267822B2 (en) | 2017-09-13 | 2022-03-08 | The Regents Of The University Of Michigan | BET bromodomain protein degraders with cleavable linkers |
| CN109503618A (zh) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | 一种brd4抑制剂 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN108084193A (zh) * | 2017-12-19 | 2018-05-29 | 郭守东 | 一种brd4蛋白抑制剂 |
| CN108129484B (zh) * | 2017-12-19 | 2021-04-27 | 郭守东 | 杂芳环衍生物 |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| JP2021521219A (ja) | 2018-04-18 | 2021-08-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｂｅｔ阻害剤およびプロテアソーム阻害剤を用いる併用療法 |
| EA202092635A1 (ru) | 2018-06-13 | 2021-03-23 | Дибли Аг | Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CN108743591A (zh) * | 2018-07-17 | 2018-11-06 | 苏州大学 | 用于治疗癌症的药物组合物及其应用 |
| US12030880B2 (en) | 2018-07-25 | 2024-07-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof |
| CN120468320A (zh) * | 2018-10-09 | 2025-08-12 | 加利福尼亚大学董事会 | E3连接酶的共价靶向 |
| AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| CN113164477A (zh) | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF |
| WO2020169698A1 (en) | 2019-02-21 | 2020-08-27 | F. Hoffmann-La Roche Ag | Sensitization of cancer cells to tnf by bet inhibition |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102201902B1 (ko) * | 2019-04-22 | 2021-01-11 | 건국대학교 글로컬산학협력단 | 암을 진단하기 위한 마커인 sox9 및 brd4, 및 이들을 이용한 암 예측 방법 |
| WO2020234445A1 (en) | 2019-05-23 | 2020-11-26 | F. Hoffmann-La Roche Ag | Combination therapy with a bet inhibitor and a bcl-2 inhibitor |
| US12636370B2 (en) | 2019-08-08 | 2026-05-26 | Institute For Cancer Research | Combination therapy for treatment of cancer |
| WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
| US12692273B2 (en) | 2019-11-01 | 2026-07-28 | The Regents Of The University Of California | p53 modulators and uses thereof |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN111529533B (zh) * | 2020-06-05 | 2021-06-11 | 南华大学附属第一医院 | 溴结构域蛋白4抑制剂jq1或其衍生物在制备治疗脓毒症肠屏障损伤药物中的应用 |
| AR122707A1 (es) | 2020-06-23 | 2022-09-28 | Genentech Inc | Compuestos macrocíclicos y métodos de uso de los mismos |
| WO2022046682A1 (en) * | 2020-08-26 | 2022-03-03 | Mdi Biological Laboratory | Bromodomain and extra terminal domain (bet) inhibitor compositions and methods thereof for use as anti-aging agents |
| WO2022236173A1 (en) * | 2021-05-07 | 2022-11-10 | Mayo Foundation For Medical Education And Research | Treating liver disease |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| CA3255932A1 (en) | 2022-04-19 | 2023-10-26 | Nuevolution A/S | ACTIVE COMPOUNDS AGAINST BROMODOMAINS |
| EP4774278A1 (en) * | 2023-09-08 | 2026-07-15 | The Regents of The University of California | Small molecule enhancers of secreted clusterin (sclu) |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3709898A (en) * | 1971-02-09 | 1973-01-09 | Upjohn Co | Process for the production of triazolobenzodiazepines and intermediates |
| US3681343A (en) * | 1971-05-11 | 1972-08-01 | Upjohn Co | 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines |
| US3812259A (en) * | 1971-08-09 | 1974-05-21 | Upjohn Co | Animal feed and process |
| CH622019A5 (en) | 1975-10-23 | 1981-03-13 | Upjohn Co | Process for the preparation of aminotriazolobenzodiazepines |
| FR2329668A1 (fr) * | 1975-10-27 | 1977-05-27 | Upjohn Co | Procede de preparation d'aminotriazolobenzodiazepines |
| EP0087850A1 (en) | 1982-01-04 | 1983-09-07 | The Upjohn Company | Benzodiazepines for anti-hypertensive use |
| DE3435973A1 (de) | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung |
| DE3724164A1 (de) | 1986-07-25 | 1988-01-28 | Boehringer Ingelheim Kg | Neue 1,4-benzodiazepine, ihre herstellung und verwendung |
| DE3878833T2 (de) | 1987-05-28 | 1993-06-09 | Yoshitomi Pharmaceutical | Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben. |
| JPH0676326B2 (ja) | 1988-05-24 | 1994-09-28 | 吉富製薬株式会社 | 循環器系疾患治療薬 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
| EP0387613A1 (de) | 1989-03-03 | 1990-09-19 | Boehringer Ingelheim Kg | Neue Thienodiazepine |
| CA2020806A1 (en) | 1989-07-12 | 1991-01-13 | Karl-Heinz Weber | Thienodiazepine derivatives |
| JPH0396299A (ja) | 1989-09-08 | 1991-04-22 | Asahi Tec Corp | ブラウン管等の電磁遮へい装置 |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| JP3239364B2 (ja) | 1991-10-11 | 2001-12-17 | ウェルファイド株式会社 | 骨粗鬆症治療薬およびジアゼピン化合物 |
| WO1994006802A1 (fr) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| WO1994022872A1 (fr) | 1993-03-30 | 1994-10-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Inhibiteur d'adhesion cellulaire et compose a base de thienotriazolodiazepine |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| CN1168140A (zh) | 1995-01-06 | 1997-12-17 | 弗·哈夫曼-拉罗切有限公司 | 羟甲基咪唑并二氮杂䓬及其酯 |
| US5978740A (en) | 1995-08-09 | 1999-11-02 | Vertex Pharmaceuticals Incorporated | Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them |
| CN1101680C (zh) | 1995-09-09 | 2003-02-19 | 弗·哈夫曼-拉罗切有限公司 | 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 |
| PL330635A1 (en) | 1996-06-12 | 1999-05-24 | Japan Tobacco Inc | Inhibitor of cytokin production, triazepin compound and intermediate compounds used for obtaining the last mentioned one |
| WO1998011111A1 (en) | 1996-09-13 | 1998-03-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienotriazolodiazepine compounds and medicinal uses thereof |
| US6444664B1 (en) | 1997-04-18 | 2002-09-03 | Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) | Method for controlling the plasma level of lipoproteins to treat alzheimeris disease |
| US6183121B1 (en) | 1997-08-14 | 2001-02-06 | Vertex Pharmaceuticals Inc. | Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets |
| JPH11228576A (ja) | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| KR20000016732A (en) | 1998-12-12 | 2000-03-25 | Japan Tobacco Inc | Cytokine production inhibitors, triazepine compounds, and intermediates thereof |
| EE200100603A (et) | 1999-05-14 | 2003-02-17 | Imclone Systems Incorporated | Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega |
| US7589167B2 (en) * | 2000-02-22 | 2009-09-15 | J. David Gladstone Institutes | ZA loops of bromodomains |
| JP4875277B2 (ja) | 2000-06-16 | 2012-02-15 | 田辺三菱製薬株式会社 | 放出ｐＨ域及び／又は速度制御組成物 |
| US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
| US20060142257A1 (en) | 2001-01-19 | 2006-06-29 | Eberhard Nieschlag | Male contraceptive formulation comprising norethisterone |
| US6979682B2 (en) | 2001-02-23 | 2005-12-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast |
| US20030216758A1 (en) | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| PL378116A1 (pl) | 2003-02-27 | 2006-03-06 | Abbott Laboratories | Heterocykliczne inhibitory kinazy |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1656155A2 (en) | 2003-06-02 | 2006-05-17 | Ohio University | Use of genes differentially expressed during aging of liver for treatment and diagnosis |
| WO2005002526A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Method and compositions for treatment of viral infections |
| AU2004272288B2 (en) | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| EP1528056A1 (en) | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| WO2006129623A1 (ja) * | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| WO2007014838A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US20070105887A1 (en) | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations of temsirolimus and sunitinib malate |
| WO2007076348A2 (en) | 2005-12-23 | 2007-07-05 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
| KR101062583B1 (ko) | 2006-01-17 | 2011-09-06 | 에프. 호프만-라 로슈 아게 | Ｇａｂａ 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-ａ]피리딘 |
| ATE479434T1 (de) | 2006-02-14 | 2010-09-15 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
| US20070218135A1 (en) | 2006-03-14 | 2007-09-20 | Glenmark Pharmaceuticals Limited | Sustained release matrix pharmaceutical composition |
| DE602007008553D1 (de) | 2006-05-03 | 2010-09-30 | Novartis Ag | Verwendung von organischen verbindungen |
| ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| DK2474523T3 (da) | 2006-12-26 | 2020-07-13 | Lantheus Medical Imaging Inc | Ligander til billeddannelse af hjerte-innervation |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| WO2008137081A1 (en) | 2007-05-02 | 2008-11-13 | The Trustees Of Columbia University In The City Of New York | Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives |
| KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
| CA2710118A1 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
| CN101910182B (zh) * | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| US20110098288A1 (en) | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
| WO2010015340A1 (en) | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
| CN102292341B (zh) | 2008-10-30 | 2014-09-10 | 环行医学有限责任公司 | 对apo a有活性的噻吩并三唑并二氮杂*衍生物 |
| EP2379559B1 (en) | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| EP2389379A1 (en) | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CA2779355C (en) | 2009-11-05 | 2018-01-16 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| AU2010317096B2 (en) | 2009-11-05 | 2015-03-26 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| US20120329803A1 (en) | 2010-02-17 | 2012-12-27 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| WO2011143651A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| JP5715241B2 (ja) | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| EP2585465B1 (en) | 2010-06-22 | 2014-11-12 | GlaxoSmithKline LLC | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| US20120014979A1 (en) | 2010-07-16 | 2012-01-19 | Alexander Dent | Use of bcl6 inhibitors for treating autoimmune diseases |
| TWI583689B (zh) | 2010-08-04 | 2017-05-21 | 達納 法柏癌症學院有限公司 | 治療腫瘤形成、發炎疾病及其他病症之組成物及方法 |
| CN107050456B (zh) | 2010-09-28 | 2022-08-12 | 加利福尼亚大学董事会 | 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合 |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US20130004481A1 (en) | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US20120244209A1 (en) | 2011-03-02 | 2012-09-27 | Roth Jack A | Tusc2 therapies |
| CA2843643A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| WO2013033420A1 (en) | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013123521A1 (en) | 2012-02-17 | 2013-08-22 | Nexbio, Inc. | Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients |
| US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
| EP2861255B1 (en) | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| WO2014068402A2 (en) | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| WO2014071247A1 (en) | 2012-11-02 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors |
| HK1212972A1 (zh) | 2013-02-22 | 2016-06-24 | Bayer Pharma Aktiengesellschaft | 作爲bet-蛋白抑制剂用於治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓 |
| CA2901805A1 (en) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| JP2016510039A (ja) | 2013-02-28 | 2016-04-04 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法 |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| CA2906100A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Treating th2-mediated diseases by inhibition of bromodomains |
| CA2913741A1 (en) | 2013-05-28 | 2014-12-04 | The Brigham And Women's Hospital, Inc. | Bet inhibition therapy for heart disease |
| DE102013106353B4 (de) | 2013-06-18 | 2018-06-28 | Tdk Corporation | Verfahren zum Aufbringen einer strukturierten Beschichtung auf ein Bauelement |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| CN105899212A (zh) | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| EP3033423A4 (en) | 2013-08-16 | 2017-04-26 | Rana Therapeutics Inc. | Epigenetic regulators of frataxin |
| AU2014323526B2 (en) | 2013-09-19 | 2020-07-23 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
| CN105979958A (zh) | 2013-10-11 | 2016-09-28 | 基因泰克公司 | Cbp/ep300布罗莫结构域抑制剂用于癌症免疫疗法的用途 |
| US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| WO2015081284A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| WO2015117083A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| WO2015131113A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| UA122130C2 (uk) | 2014-10-27 | 2020-09-25 | Тенша Терапеутікс, Інк. | Інгібітори бромодомену |
| RU2745999C1 (ru) | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| AU2016283020A1 (en) | 2015-06-26 | 2018-01-04 | Tensha Therapeutics, Inc. | Treatment of nut midline carcinoma |
| MA43037A (fr) | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Inst Inc | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
-
2011
- 2011-05-16 ES ES14197043.4T patent/ES2606958T3/es active Active
- 2011-05-16 BR BR122014024883-0A patent/BR122014024883A2/pt active Search and Examination
- 2011-05-16 SI SI201131043A patent/SI2902030T1/sl unknown
- 2011-05-16 PL PL11781422T patent/PL2571503T3/pl unknown
- 2011-05-16 HU HUE14197043A patent/HUE031073T2/en unknown
- 2011-05-16 CA CA2799420A patent/CA2799420C/en active Active
- 2011-05-16 PL PL14197043T patent/PL2902030T3/pl unknown
- 2011-05-16 EP EP11781422.8A patent/EP2571503B1/en active Active
- 2011-05-16 CN CN201180033582.8A patent/CN103037865B/zh active Active
- 2011-05-16 MX MX2019000599A patent/MX384074B/es unknown
- 2011-05-16 US US13/698,010 patent/US8981083B2/en active Active
- 2011-05-16 MX MX2012013255A patent/MX2012013255A/es active IP Right Grant
- 2011-05-16 AU AU2011252808A patent/AU2011252808B2/en active Active
- 2011-05-16 MX MX2015008841A patent/MX362384B/es unknown
- 2011-05-16 WO PCT/US2011/036701 patent/WO2011143669A2/en not_active Ceased
- 2011-05-16 CN CN201410494811.1A patent/CN104311562B/zh active Active
- 2011-05-16 KR KR1020127032668A patent/KR101857599B1/ko active Active
- 2011-05-16 DK DK11781422.8T patent/DK2571503T3/en active
- 2011-05-16 PT PT117814228T patent/PT2571503E/pt unknown
- 2011-05-16 EP EP14197043.4A patent/EP2902030B1/en active Active
- 2011-05-16 ES ES11781422.8T patent/ES2534521T3/es active Active
- 2011-05-16 BR BR112012029005A patent/BR112012029005A2/pt active Search and Examination
-
2012
- 2012-11-12 IL IL222993A patent/IL222993A/en active IP Right Grant
-
2014
- 2014-09-30 US US14/502,840 patent/US9320741B2/en active Active
-
2015
- 2015-05-18 IL IL238869A patent/IL238869A0/en unknown
- 2015-05-18 IL IL238868A patent/IL238868A0/en unknown
-
2016
- 2016-03-04 US US15/061,576 patent/US20170029437A1/en not_active Abandoned
-
2018
- 2018-02-01 US US15/886,559 patent/US10407441B2/en active Active
-
2019
- 2019-07-19 US US16/516,918 patent/US20200148702A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238869A0 (en) | Preparations and methods for treating calluses, inflammatory disease and other disorders | |
| IL253870A0 (en) | Certain amino-pyrimidines, their assemblies, and methods of using them | |
| IL250824B (en) | Certain amino-pyrimidines, their assemblies, and methods of using them | |
| ZA201205683B (en) | Probiotic composition for use in the treatment of bowel inflammation | |
| EP2646468A4 (en) | ANTI-NGF COMPOSITIONS AND THEIR USE | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| IL235923A0 (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof | |
| PL2771041T3 (pl) | Kompozycje i ich zastosowanie w gojeniu się kości | |
| IL215684A0 (en) | Trehalulose-containing composition, its preparation and use | |
| ZA201304026B (en) | Folic acid-ramipril combination:cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| EP2599490A4 (en) | COMPOSITION FOR TREATMENT OF INJURY, FORMULATION AND USE THEREOF | |
| ZA201207178B (en) | Oxadiazole compounds,their preparation and use | |
| ZA201301608B (en) | Compositions comprising oleuropeins and flavanoids and their use | |
| EP2668044A4 (en) | COMPOSITIONS AND THEIR USE | |
| GB0902429D0 (en) | Compositions and their use | |
| ZA201206898B (en) | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferatiive disorders | |
| SI2603217T1 (sl) | Novi 6,7-disubstituirani-isokinolinski derivati in njihova uporaba | |
| GB201005826D0 (en) | New compositions and their use | |
| HK1179853A (en) | Aptamers to 4-1bb and their use in treating diseases and disorders |